ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE and CHRONIC KIDNEY DISEASE

2,605 reports of this reaction

6.1% of all ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE reports

#2 most reported adverse reaction

Overview

CHRONIC KIDNEY DISEASE is the #2 most commonly reported adverse reaction for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, manufactured by Gilead Sciences, Inc.. There are 2,605 FDA adverse event reports linking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE to CHRONIC KIDNEY DISEASE. This represents approximately 6.1% of all 43,023 adverse event reports for this drug.

Patients taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE who experience chronic kidney disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

CHRONIC KIDNEY DISEASE2,605 of 43,023 reports

CHRONIC KIDNEY DISEASE is moderately reported among ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE users, representing a notable but not dominant share of adverse events.

Other Side Effects of ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE

In addition to chronic kidney disease, the following adverse reactions have been reported for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE:

Other Drugs Associated with CHRONIC KIDNEY DISEASE

The following drugs have also been linked to chronic kidney disease in FDA adverse event reports:

ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDEALUMINUM HYDROXIDE AND MAGNESIUM CARBONATEAMMONIUM LACTATEAMOXICILLINAMPICILLINAMPICILLIN SODIUMASPIRIN AND CAFFEINEATAZANAVIRAVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, OXYBENZONEAZITHROMYCINAZITHROMYCIN DIHYDRATEAZITHROMYCIN MONOHYDRATEBARIUM SULFATEBENZOCAINE AND MENTHOLBENZONATATEBICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATEBISMUTH SUBSALICYLATEBUFFERED ASPIRINBUMETANIDECALCITRIOL

Frequently Asked Questions

Does ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE cause CHRONIC KIDNEY DISEASE?

CHRONIC KIDNEY DISEASE has been reported as an adverse event in 2,605 FDA reports for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is CHRONIC KIDNEY DISEASE with ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE?

CHRONIC KIDNEY DISEASE accounts for approximately 6.1% of all adverse event reports for ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, making it one of the most commonly reported side effect.

What should I do if I experience CHRONIC KIDNEY DISEASE while taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE?

If you experience chronic kidney disease while taking ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages

ELVITEGRAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE Full ProfileAll Drugs Causing CHRONIC KIDNEY DISEASEGilead Sciences, Inc. Drugs
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.